FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141720111> ?p ?o ?g. }

• W2141720111 endingPage "880" @default.
• W2141720111 startingPage "868" @default.
• W2141720111 abstract "Integrins are the major adhesive molecules in mammalian cells. Each integrin subtype plays a unique role in cell differentiation and embryo development. However, integrin involvement in carcinogenesis has not been well defined.We identified mutations in integrin alpha7 by sequencing genomic DNAs and cDNAs from 122 specimens, including 62 primary human tumor samples, four cell lines, and 56 matched normal tissues. We evaluated the tumor suppressor activity of integrin alpha7 with colony formation, soft agar colony growth, and cell migration assays by forcing its expression in PC-3 and Du145 prostate cancer cells and SK-UT-1 leiomyosarcoma cells. PC-3 and Du145 xenograft tumors with increased levels of integrin alpha7 in severe combined immune deficient mice were used to assess the effect of integrin alpha7 on tumor growth and metastasis. Immunostaining was used to localize and to measure the level of integrin alpha7 in 701 and 141 specimens of prostate and smooth muscle, respectively. A meta-analysis of integrin alpha7 mRNA microarray data from four studies was performed. Kaplan-Meier analyses were used to assess survival. All statistical tests were two-sided.Integrin alpha7 mutations that generate truncations were found in specimens of 16 of 28 prostate cancers (57%, 95% confidence interval [CI] = 37% to 76%), five of 24 hepatocellular carcinomas (21%, 95% CI = 7% to 42%), five of six glioblastomas multiforme (83%, 95% CI = 36% to 99%), and one of four leiomyosarcomas (25%, 95% CI = 0.6% to 81%). Integrin alpha7 mutations were associated with increased recurrence of human prostate cancer (nine recurrences among 13 patients with integrin alpha7 mutations versus one among eight without such mutations; odds ratio [OR] = 14, 95% CI = 1.15 to 782, P = .024) and hepatocellular carcinoma (five recurrences among eight patients with integrin alpha7 mutations versus one among 16 without such mutations, OR = 21, 95% CI = 1.6 to 1245; P = .007). Forced expression of normal integrin alpha7 in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and metastasis both in vitro and in vivo. Focal or no integrin alpha7 expression in human prostate cancer and soft tissue leiomyosarcoma was associated with a reduction of metastasis-free survival (for example, for prostate cancer with focal or no expression, 5-year metastasis-free survival was 32%, 95% CI = 24.4% to 40.3%, and for prostate cancer with at least weak expression, it was 85%, 95% CI = 79% to 91%; P<.001). Microarray analysis indicated that cyclin D kinase inhibitor 3 and GTPase-activating protein may be possible targets for integrin alpha7-mediated tumor suppressor activity and inhibition of cell motility.Integrin alpha7 appears to be a tumor suppressor that operates by suppressing tumor growth and retarding migration." @default.
• W2141720111 created "2016-06-24" @default.
• W2141720111 creator A5002316087 @default.
• W2141720111 creator A5006995434 @default.
• W2141720111 creator A5016331956 @default.
• W2141720111 creator A5018355628 @default.
• W2141720111 creator A5023821329 @default.
• W2141720111 creator A5037387251 @default.
• W2141720111 creator A5050299013 @default.
• W2141720111 creator A5053870799 @default.
• W2141720111 creator A5069300507 @default.
• W2141720111 date "2007-06-06" @default.
• W2141720111 modified "2023-09-27" @default.
• W2141720111 title "Analysis of Integrin α7 Mutations in Prostate Cancer, Liver Cancer, Glioblastoma Multiforme, and Leiomyosarcoma" @default.
• W2141720111 cites W1555181940 @default.
• W2141720111 cites W1565483293 @default.
• W2141720111 cites W1576773659 @default.
• W2141720111 cites W1668763770 @default.
• W2141720111 cites W1946731981 @default.
• W2141720111 cites W1967983126 @default.
• W2141720111 cites W1969871009 @default.
• W2141720111 cites W1971019443 @default.
• W2141720111 cites W2000327471 @default.
• W2141720111 cites W2001296918 @default.
• W2141720111 cites W2006868309 @default.
• W2141720111 cites W2007932023 @default.
• W2141720111 cites W2016787034 @default.
• W2141720111 cites W2042799534 @default.
• W2141720111 cites W2052569682 @default.
• W2141720111 cites W2065735233 @default.
• W2141720111 cites W2071993841 @default.
• W2141720111 cites W2076131436 @default.
• W2141720111 cites W2104096208 @default.
• W2141720111 cites W2104713336 @default.
• W2141720111 cites W2108426942 @default.
• W2141720111 cites W2157634892 @default.
• W2141720111 cites W2242558815 @default.
• W2141720111 doi "https://doi.org/10.1093/jnci/djk199" @default.
• W2141720111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17551147" @default.
• W2141720111 hasPublicationYear "2007" @default.
• W2141720111 type Work @default.
• W2141720111 sameAs 2141720111 @default.
• W2141720111 citedByCount "63" @default.
• W2141720111 countsByYear W21417201112013 @default.
• W2141720111 countsByYear W21417201112014 @default.
• W2141720111 countsByYear W21417201112015 @default.
• W2141720111 countsByYear W21417201112016 @default.
• W2141720111 countsByYear W21417201112017 @default.
• W2141720111 countsByYear W21417201112018 @default.
• W2141720111 countsByYear W21417201112019 @default.
• W2141720111 countsByYear W21417201112020 @default.
• W2141720111 countsByYear W21417201112021 @default.
• W2141720111 countsByYear W21417201112023 @default.
• W2141720111 crossrefType "journal-article" @default.
• W2141720111 hasAuthorship W2141720111A5002316087 @default.
• W2141720111 hasAuthorship W2141720111A5006995434 @default.
• W2141720111 hasAuthorship W2141720111A5016331956 @default.
• W2141720111 hasAuthorship W2141720111A5018355628 @default.
• W2141720111 hasAuthorship W2141720111A5023821329 @default.
• W2141720111 hasAuthorship W2141720111A5037387251 @default.
• W2141720111 hasAuthorship W2141720111A5050299013 @default.
• W2141720111 hasAuthorship W2141720111A5053870799 @default.
• W2141720111 hasAuthorship W2141720111A5069300507 @default.
• W2141720111 hasBestOaLocation W21417201111 @default.
• W2141720111 hasConcept C121608353 @default.
• W2141720111 hasConcept C142724271 @default.
• W2141720111 hasConcept C1491633281 @default.
• W2141720111 hasConcept C195687474 @default.
• W2141720111 hasConcept C2776235491 @default.
• W2141720111 hasConcept C2776438761 @default.
• W2141720111 hasConcept C2777532014 @default.
• W2141720111 hasConcept C2779013556 @default.
• W2141720111 hasConcept C2779723316 @default.
• W2141720111 hasConcept C2780192828 @default.
• W2141720111 hasConcept C502942594 @default.
• W2141720111 hasConcept C54355233 @default.
• W2141720111 hasConcept C555283112 @default.
• W2141720111 hasConcept C71924100 @default.
• W2141720111 hasConcept C86803240 @default.
• W2141720111 hasConceptScore W2141720111C121608353 @default.
• W2141720111 hasConceptScore W2141720111C142724271 @default.
• W2141720111 hasConceptScore W2141720111C1491633281 @default.
• W2141720111 hasConceptScore W2141720111C195687474 @default.
• W2141720111 hasConceptScore W2141720111C2776235491 @default.
• W2141720111 hasConceptScore W2141720111C2776438761 @default.
• W2141720111 hasConceptScore W2141720111C2777532014 @default.
• W2141720111 hasConceptScore W2141720111C2779013556 @default.
• W2141720111 hasConceptScore W2141720111C2779723316 @default.
• W2141720111 hasConceptScore W2141720111C2780192828 @default.
• W2141720111 hasConceptScore W2141720111C502942594 @default.
• W2141720111 hasConceptScore W2141720111C54355233 @default.
• W2141720111 hasConceptScore W2141720111C555283112 @default.
• W2141720111 hasConceptScore W2141720111C71924100 @default.
• W2141720111 hasConceptScore W2141720111C86803240 @default.
• W2141720111 hasIssue "11" @default.
• W2141720111 hasLocation W21417201111 @default.
• W2141720111 hasLocation W21417201112 @default.
• W2141720111 hasOpenAccess W2141720111 @default.

• next